• Skip to main content
  • Skip to footer
Minority News Logo

Black Radio Network

The world you see depends upon the news you get. ®

Home › RSS › Pint Pharma announces the approval of ORLADEYO® (berotralstat), the first oral therapy indicated to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older in Peru.

Pint Pharma announces the approval of ORLADEYO® (berotralstat), the first oral therapy indicated to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older in Peru.

July 9, 2024 by |

LIMA, Peru–(BUSINESS WIRE)– #angioedemahereditario–It is a great pleasure to announce that the General Directorate of Medicines Supplies and Drugs (DIGEMID) in Peru has approved the daily oral use of ORLADEYO® (berotralstat) for prophylaxis of hereditary angioedema (HAE) attacks in adults and children 12 years and older. Hereditary angioedema is a genetic disorder that causes recurrent episodes of sudden, painful swelling of the skin, mucous membranes, and submucosal tissues. Until recently, treatment options for HA

Filed Under: RSS

Footer

To Reach Us


Email:
news@blackradionetwork.com
news@minoritynews.net
news@minoritynewsservice.com

Address:
Black Radio Network
375 Fifth Avenue
New York, NY 10016

Phone Numbers:
Ph # (212) 686-6850
Fx # (212) 686-7308


Copyright © 2025 · Black Radio Network, Inc. All rights reserved. · About · Privacy · Terms of Use